---
document_datetime: 2026-01-07 14:36:57
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/apremilast-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: apremilast-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5546524
conversion_datetime: 2026-01-10 11:06:28.291573
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Apremilast Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 07/01/2026                          |                                             | Labelling                        |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000317881                      | Update of the product information to introduce the following changes to the labelling: - to align the grey-shading of the pharmaceutical form in section '4. Pharmaceutical form and contents' of the 'Particulars to appear on the outer packaging' with all other presentations - to update 'For oral use' to 'Oral use' in section '5. Method and route(s) of administration' of the 'Particulars to appear on the outer packaging' - to grey-shade all blister text of the 'Minimum particulars to appear on blisters or strips' for the wallet card initiation packs - to align the grey-shading of '2D barcode carrying the unique identifier included' in section '17. Unique identifier -2D barcode' of the 'Particulars to appear on the outer packaging' with all other presentations. - to harmonise the grey- shading of the marketing authorisation number in section '12. Marketing authorisation number(s)' of the 'Particulars to appear on the outer packaging' where applicable. Additionally, the MAH took the   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000280853 | This was an application for a group of variations. A.5 Change in the name and/or address of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|